GB201914516D0 - Treatment of eye disease - Google Patents

Treatment of eye disease

Info

Publication number
GB201914516D0
GB201914516D0 GB201914516A GB201914516A GB201914516D0 GB 201914516 D0 GB201914516 D0 GB 201914516D0 GB 201914516 A GB201914516 A GB 201914516A GB 201914516 A GB201914516 A GB 201914516A GB 201914516 D0 GB201914516 D0 GB 201914516D0
Authority
GB
United Kingdom
Prior art keywords
treatment
eye disease
eye
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201914516A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB BALTYMAS
Original Assignee
UAB BALTYMAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB BALTYMAS filed Critical UAB BALTYMAS
Priority to GB201914516A priority Critical patent/GB201914516D0/en
Publication of GB201914516D0 publication Critical patent/GB201914516D0/en
Priority to JP2022521196A priority patent/JP2023500033A/ja
Priority to US17/767,232 priority patent/US20220370554A1/en
Priority to KR1020227015264A priority patent/KR20220079917A/ko
Priority to EP20789562.4A priority patent/EP4041280A1/en
Priority to PCT/EP2020/078173 priority patent/WO2021069523A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GB201914516A 2019-10-08 2019-10-08 Treatment of eye disease Ceased GB201914516D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB201914516A GB201914516D0 (en) 2019-10-08 2019-10-08 Treatment of eye disease
JP2022521196A JP2023500033A (ja) 2019-10-08 2020-10-07 血管新生性眼疾患を治療又は予防するためのカルレティキュリン
US17/767,232 US20220370554A1 (en) 2019-10-08 2020-10-07 Calreticulin for Treating or Preventing an Angiogenic Eye Disease
KR1020227015264A KR20220079917A (ko) 2019-10-08 2020-10-07 혈관신생 안 질환의 치료 또는 예방을 위한 칼레티쿨린
EP20789562.4A EP4041280A1 (en) 2019-10-08 2020-10-07 Calreticulin for treating or preventing an angiogenic eye disease
PCT/EP2020/078173 WO2021069523A1 (en) 2019-10-08 2020-10-07 Calreticulin for treating or preventing an angiogenic eye disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201914516A GB201914516D0 (en) 2019-10-08 2019-10-08 Treatment of eye disease

Publications (1)

Publication Number Publication Date
GB201914516D0 true GB201914516D0 (en) 2019-11-20

Family

ID=68541456

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201914516A Ceased GB201914516D0 (en) 2019-10-08 2019-10-08 Treatment of eye disease

Country Status (6)

Country Link
US (1) US20220370554A1 (enExample)
EP (1) EP4041280A1 (enExample)
JP (1) JP2023500033A (enExample)
KR (1) KR20220079917A (enExample)
GB (1) GB201914516D0 (enExample)
WO (1) WO2021069523A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699506A (zh) * 2021-12-30 2022-07-05 北京百华百汇生物科技有限公司 重组钙网蛋白在生发、育发、保护毛发或防脱发中的用途和相关产品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020577A1 (en) 1998-10-06 2000-04-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
US6867180B1 (en) 1998-10-06 2005-03-15 The United States Of America As Represented By The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
WO2011160082A2 (en) * 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
TWI445543B (zh) 2012-05-03 2014-07-21 Univ Nat Sun Yat Sen 一種用以治療眼部脈絡膜血管新生之醫藥組合物
WO2014011723A1 (en) 2012-07-12 2014-01-16 Uab Baltymas Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system

Also Published As

Publication number Publication date
US20220370554A1 (en) 2022-11-24
WO2021069523A1 (en) 2021-04-15
EP4041280A1 (en) 2022-08-17
JP2023500033A (ja) 2023-01-04
KR20220079917A (ko) 2022-06-14

Similar Documents

Publication Publication Date Title
IL276383B1 (en) Treatment of ophthalmological diseases
IL281773B2 (en) Ophthalmic preparation for the treatment of dry eye disease
PL3399962T3 (pl) Kompozycja okulistyczna do leczenia choroby suchego oka
IL289405A (en) Personalized treatment of eye diseases
ZA202108219B (en) Combination treatment of arthritic disease
HUE066769T2 (hu) Neurodegeneratív szembetegség kezelése pridopidinnal
PL3886858T3 (pl) Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem
IL282361A (en) Treatment for neurological diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
IL269698B (en) Methods for preventing or treating eye diseases
PL3603621T3 (pl) Liposomy do leczenia chorób oczu
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
GB201910645D0 (en) Treatment for dry eye disease
IL289221A (en) Compounds for the treatment of vision disorders
GB201907305D0 (en) Treatment of conditions
EP3658218A4 (en) Treatment of eye disorders
IL291626A (en) Celiac treatment
IL286099A (en) Methods of treating disease with levoketoconazole
IL263837A (en) Treatment of ocular disease
GB201916506D0 (en) Corneal tissue
GB201811912D0 (en) Treatment of disease
GB201811911D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)